UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 312

Sortiert nach

Comparison of multivariate linear regression and a machine learning algorithm developed for prediction of precision warfarin dosing in a Korean population

Journal of thrombosis and haemostasis, 2021-07, Vol.19 (7), p.1676-1686

2021

Volltextzugriff (PDF)

Molecular perturbations in pulmonary tuberculosis patients identified by pathway-level analysis of plasma metabolic features

PloS one, 2022-01, Vol.17 (1), p.e0262545-e0262545

2022

Volltextzugriff (PDF)

Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis

Journal of clinical pharmacology, 2021-12, Vol.61 (12), p.1567-1578

2021

Volltextzugriff (PDF)

Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

Molecules (Basel, Switzerland), 2022-12, Vol.27 (23), p.8607

2022

Volltextzugriff (PDF)

Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management

Pharmaceutics, 2022-05, Vol.14 (5), p.990

2022

Volltextzugriff (PDF)

Comprehensive lipid and lipid-related gene investigations of host immune responses to characterize metabolism-centric biomarkers for pulmonary tuberculosis

Scientific reports, 2022-08, Vol.12 (1), p.13395-13395, Article 13395

2022

Volltextzugriff (PDF)

CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPARγ Receptor

Pharmaceuticals (Basel, Switzerland), 2023-04, Vol.16 (4), p.593

2023

Volltextzugriff (PDF)

Para‐aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research

British journal of clinical pharmacology, 2022-03, Vol.88 (3), p.1159-1169

2022

Volltextzugriff (PDF)

Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers

Clinical therapeutics, 2018-12, Vol.40 (12), p.2050-2064

2018

Volltextzugriff (PDF)

The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population

BMC medical genomics, 2022-01, Vol.15 (1), p.3-3, Article 3

2022

Volltextzugriff (PDF)

Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring

Biomedicine & pharmacotherapy, 2023-02, Vol.158, p.114187-114187, Article 114187

2023

Volltextzugriff (PDF)

Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer

Journal of clinical pharmacology, 2019-11, Vol.59 (11), p.1543-1550

2019

Volltextzugriff (PDF)

Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis

International journal of infectious diseases, 2022-04, Vol.117, p.8-14

2022

Volltextzugriff (PDF)

Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371

Clinical therapeutics, 2019-01, Vol.41 (1), p.92-106

2019

Volltextzugriff (PDF)

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19

Translational and Clinical Pharmacology, 2022, 30(1), , pp.24-36

2022

Volltextzugriff (PDF)

Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers

Frontiers in immunology, 2023-10, Vol.14, p.1210372-1210372

2023

Volltextzugriff (PDF)

Advancing personalized medicine for tuberculosis through the application of immune profiling

Frontiers in cellular and infection microbiology, 2023-02, Vol.13, p.1108155-1108155

2023

Volltextzugriff (PDF)

Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil

Journal of clinical pharmacology, 2018-07, Vol.58 (7), p.905-912

2018

Volltextzugriff (PDF)

Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance

Frontiers in pharmacology, 2023-05, Vol.14, p.1116226-1116226

2023

Volltextzugriff (PDF)

Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database

BMC pulmonary medicine, 2023-11, Vol.23 (1), p.1-471, Article 471

2023

Volltextzugriff (PDF)

The structures of the kinase domain and UBA domain of MPK38 suggest the activation mechanism for kinase activity

Acta crystallographica. Section D, Biological crystallography., 2014-02, Vol.70 (2), p.514-521

2014

Volltextzugriff (PDF)

Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation

Healthcare Informatics Research, 2022, 28(2), , pp.176-180

2022

Volltextzugriff (PDF)

Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting

Journal of Korean medical science, 2024-04, Vol.39 (13), p.e104-e104

2024

Volltextzugriff (PDF)

Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis

Clinical therapeutics, 2022-01, Vol.44 (1), p.67-80.e1

2022

Volltextzugriff (PDF)

Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro

Antimicrobial agents and chemotherapy, 2022-10, Vol.66 (10), p.e0056522-e0056522

2022

Volltextzugriff (PDF)

1 – 25 von 312

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(272)
Mit Volltextzugriff
(260)

Publikationsform

Sprache

Englisch
(251)
Koreanisch
(60)
Japanisch
(42)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Comparison of multivariate linear regression and a machine learning algorithm developed for prediction of precision warfarin dosing in a Korean population

Molecular perturbations in pulmonary tuberculosis patients identified by pathway-level analysis of plasma metabolic features

Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis

Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management

Comprehensive lipid and lipid-related gene investigations of host immune responses to characterize metabolism-centric biomarkers for pulmonary tuberculosis

CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPARγ Receptor

Para‐aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research

Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers

The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population

Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring

Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer

Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis

Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19

Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers

Advancing personalized medicine for tuberculosis through the application of immune profiling

Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil

Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance

Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database

The structures of the kinase domain and UBA domain of MPK38 suggest the activation mechanism for kinase activity

Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation

Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting

Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis

Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro

Suchergebnisse filtern